U.S. biotech company Moderna will provide up to 500 million doses for the U.N.-backed program to ship coronavirus vaccines to needy people in low- and middle-income countries, but shipments won’t begin until the fourth quarter, the company and program leaders said Monday.
The advance purchase agreement from Gavi, the Vaccine Alliance, comes just days after the World Health Organization announced emergency approval of the Moderna vaccine that paves the way for its inclusion in the U.N.-backed COVAX program.
Gavi, a Geneva-based public-private partnership, has been scrambling to try to strike deals with vaccine makers at the same time as trying to persuade rich countries that have secured millions of doses — some of which they aren’t even using — to donate them to poorer ones.
Also Monday, the alliance announced that Sweden’s government has committed to donate 1 million doses of the Oxford-AstraZeneca vaccine “to help COVAX urgently address immediate-term supply delays.”
Moderna has already struck, and been delivering on, supply agreements with many rich countries, which have received millions of doses of its vaccine. WHO has repeatedly decried a lack of equity in access to COVID-19 vaccines.
The rollout of Moderna vaccines for COVAX isn’t set to begin until the fourth quarter of this year, and the vast majority of the doses in the deal — 466 million — are planned for next year. The remaining 34 million are expected this year.
Stephane Bancel, the Moderna CEO, expressed support for the COVAX mission and called the deal “an important milestone” to ensure access to its vaccine worldwide.“We recognize that many countries have limited resources to access COVID-19 vaccines,” Bancel said in a statement. “We remain committed to doing everything that we can to ending this ongoing pandemic with our mRNA COVID-19 vaccine.”
The company said the doses were offered “at Moderna’s lowest tiered price, in line with the company’s global access commitments,” without specifying. Gavi didn’t provide financial terms, but has said the per-dose prices of vaccines for COVAX will eventually be made public.
Many experts say the COVID-19 crisis is acute now, with India in particular facing an unprecedented surge in cases. The Moderna vaccine has generally been considered among the most effective so far in combating new variants like the one that is spreading in India.
Seth Berkley, CEO of Gavi, which is a public-private partnership, hailed the access to “yet another efficacious vaccine.”
“Expanding and having a diverse portfolio has always been a core goal for COVAX, and to remain adaptable in the face of this continually evolving pandemic – including the rising threat posed by new variants,” he said. “This agreement is a further step in that direction.”
The arrangement means Cambridge, Mass.-based Moderna can join the COVAX rollout that already includes vaccines from Oxford-AstraZeneca, which has the biggest role so far in the program, and Pfizer-BioNTech, which has committed far fewer doses to it.
Supplies of the AstraZeneca vaccine for COVAX that are being produced in India have been limited in recent month as the New Delhi government and a key Indian subcontractor — the Serum Institute of India — divert much of its production to combating the devastating outbreak at home.
The Coalition for Epidemic Preparedness and Innovation, a public-private partnership that co-manages COVAX with Gavi and WHO, made an early investment into the Moderna vaccine as the pandemic arose. The first official link-up between the company and the program has come nearly 18 months into the pandemic.
The WHO go-ahead for an emergency use listing for Moderna’s vaccine, announced late Friday, took many months because of delays that WHO faced in getting data from the manufacturer.